PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

Supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

PROGRAM OVERVIEW

It’s estimated that 30% of the approximately 9.6 million American children with atopic dermatitis (AD) suffer from moderate to severe disease. “Suffer” is the operative word, as the disease has a wide range of deleterious effects, including unrelenting itch and sleep disturbance. When suboptimally treated, this can lead to learning disabilities and behavioral disorders resulting in long-term impact on education and psychosocial health. However, medical science is rapidly unraveling the pathogenic molecular drivers of this disease and a variety of targeted treatments have recently been approved to treat children, adolescents, and even infants with moderate to severe AD. Join us for this Twitter-based Clinical Brief with experts Drs. Peter Lio, Robert Sidbury, Shawn Kwatra, and Colleen Cotton as they discuss treatments for infants, children, and adolescents with moderate to severe AD.

FACULTY CO-CHAIRS

Peter A. Lio, MD   Clinical Assistant Professor Dermatology and Pediatrics Northwestern University Feinberg School of Medicine Chicago, Illinois

Robert Sidbury, MD, MPH  Professor Department of Pediatrics University of Washington School of Medicine Division Chief, Dermatology Seattle Children’s Hospital Seattle, Washington

FACULTY DISCUSSANTS

Colleen Cotton, MD, FAAD Assistant Professor of Dermatology and Pediatrics George Washington School of Medicine and Health Sciences Attending Physician Division of Dermatology, Children’s National Hospital Washington, District of Columbia

Shawn Kwatra, MD  Director, Johns Hopkins Itch Center Associate Professor of Dermatology Johns Hopkins University School of Medicine Baltimore, Maryland

Release date: May 17, 2023 Expiration date: August 17, 2023 Estimated time to complete activity: 15 minutes

TARGET AUDIENCE

This educational activity has been designed to meet the needs of pediatric dermatologists, dermatologists, pediatricians, family practice physicians, nurse practitioners, physician assistants, and other clinicians who manage pediatric patients with atopic dermatitis.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

Select treatments for infants, children, and adolescents with moderate to severe AD based on findings from recent clinical trials

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of May 17, 2023 through August 17, 2023, participants must:

Read the learning objectives
Complete the pretest
Study the educational activity
Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 100% and a completed activity evaluation form.

MEDIA

Internet

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated. The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity: Colleen Cotton, MD, FAAD Advisory Boards: Avita, Bristol Myers Squibb, Janssen Biotech, LEO Pharma Consultant: Pierre Fabre Salary Support: Eli Lilly, Regeneron, Target RWA Speaker: Bayer, United Therapeutics Research: AbbVie, Arcutis Biotherapeutics Shawn Kwatra, MD Consultant: AbbVie, Arcutis Biotherapeutics, Aslan Pharmaceuticals, Castle Bioscience, Celldex Therapeutics, Novartis Investigator: Incyte, Pfizer, Regeneron, Sanofi, Peter Lio, MD Advisory Boards: AbbVie, Almirall, Altus Labs, Amyris, AOBiome, Arbonne, ASLAN Pharmaceuticals, Bodewell, Boston Skin Science (KPAway), Burts Bees, Castle Biosciences, Concerto Biosciences, Dermavant, Dermira, Eli Lilly, Galderma, IntraDerm, Janssen, Johnson & Johnson, Kaleido Biosciences, Kimberly-Clark, LEO, Level Ex, Lipidor AB, L'Oréal, Menlo Therapeutics, Micreos, My-Or Diagnostics, Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, SkinFix, Theraplex, Unilever, Verrica, YobeeCare Patent Holder: Theraplex AIM (patent pending) Research: AbbVie, AOBiome, Regeneron/Sanofi Genzyme Speaker: AbbVie, Eli Lilly, Galderma, Incyte, LEO, L'Oréal, Pfizer, Regeneron/Sanofi Genzyme Stock Options: Altus Labs, Boston Skin Science (KPAway), Concerto Biosciences, LearnSkin, Micreos, YobeeCare Robert Sidbury, MD, MPH Consultant: Eli Lilly, LEO Research: Castle, Galderma, Pfizer, Regeneron, UCB Speaker: Biersdorf The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent) Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS Plug-in: Adobe^® Flash^® Player 10

Adobe^® Flash^® Player 10 plug-in should be downloaded
Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below: Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Pediatric Atopic Dermatitis: Clinical Scenarios – Clinical Brief #1